These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24662821)

  • 1. Involvement of G-quadruplex structures in regulation of human RET gene expression by small molecules in human medullary thyroid carcinoma TT cells.
    Shin YJ; Kumarasamy V; Camacho D; Sun D
    Oncogene; 2015 Mar; 34(10):1292-9. PubMed ID: 24662821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.
    Kumarasamy VM; Sun D
    Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine.
    Kumarasamy VM; Shin YJ; White J; Sun D
    BMC Cancer; 2015 Aug; 15():599. PubMed ID: 26307103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer.
    Lopergolo A; Perrone R; Tortoreto M; Doria F; Beretta GL; Zuco V; Freccero M; Borrello MG; Lanzi C; Richter SN; Zaffaroni N; Folini M
    Oncotarget; 2016 Aug; 7(31):49649-49663. PubMed ID: 27351133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formation of pseudosymmetrical G-quadruplex and i-motif structures in the proximal promoter region of the RET oncogene.
    Guo K; Pourpak A; Beetz-Rogers K; Gokhale V; Sun D; Hurley LH
    J Am Chem Soc; 2007 Aug; 129(33):10220-8. PubMed ID: 17672459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents.
    Sun D; Guo K; Rusche JJ; Hurley LH
    Nucleic Acids Res; 2005; 33(18):6070-80. PubMed ID: 16239639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
    Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
    Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplex-interactive agents.
    Sun D; Liu WJ; Guo K; Rusche JJ; Ebbinghaus S; Gokhale V; Hurley LH
    Mol Cancer Ther; 2008 Apr; 7(4):880-9. PubMed ID: 18413801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.
    Gorla L; Mondellini P; Cuccuru G; Miccichè F; Cassinelli G; Cremona M; Pierotti MA; Lanzi C; Bongarzone I
    Mol Carcinog; 2009 Mar; 48(3):220-231. PubMed ID: 18756447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
    Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
    J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel dual kinase function of the RET proto-oncogene negatively regulates activating transcription factor 4-mediated apoptosis.
    Bagheri-Yarmand R; Sinha KM; Gururaj AE; Ahmed Z; Rizvi YQ; Huang SC; Ladbury JE; Bogler O; Williams MD; Cote GJ; Gagel RF
    J Biol Chem; 2015 May; 290(18):11749-61. PubMed ID: 25795775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
    Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
    JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
    Cuccuru G; Lanzi C; Cassinelli G; Pratesi G; Tortoreto M; Petrangolini G; Seregni E; Martinetti A; Laccabue D; Zanchi C; Zunino F
    J Natl Cancer Inst; 2004 Jul; 96(13):1006-14. PubMed ID: 15240784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting RET to induce medullary thyroid cancer cell apoptosis: an antagonistic interplay between PI3K/Akt and p38MAPK/caspase-8 pathways.
    Mazumdar M; Adhikary A; Chakraborty S; Mukherjee S; Manna A; Saha S; Mohanty S; Dutta A; Bhattacharjee P; Ray P; Chattopadhyay S; Banerjee S; Chakraborty J; Ray AK; Sa G; Das T
    Apoptosis; 2013 May; 18(5):589-604. PubMed ID: 23329180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.
    Smith J; Read ML; Hoffman J; Brown R; Bradshaw B; Campbell C; Cole T; Navas JD; Eatock F; Gundara JS; Lian E; Mcmullan D; Morgan NV; Mulligan L; Morrison PJ; Robledo M; Simpson MA; Smith VE; Stewart S; Trembath RC; Sidhu S; Togneri FS; Wake NC; Wallis Y; Watkinson JC; Maher ER; McCabe CJ; Woodward ER
    Hum Mol Genet; 2016 May; 25(9):1836-45. PubMed ID: 26945007
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Qi XP; Jin BY; Li PF; Wang S; Zhao YH; Cao ZL; Yu XH; Cheng J; Fang XD; Zhao JQ
    Thyroid; 2019 Oct; 29(10):1447-1456. PubMed ID: 31364476
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.
    Prazeres H; Couto JP; Rodrigues F; Vinagre J; Torres J; Trovisco V; Martins TC; Sobrinho-Simões M; Soares P
    Endocr Relat Cancer; 2011 Aug; 18(4):401-12. PubMed ID: 21551259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.
    Bim LV; Navarro FCP; Valente FOF; Lima-Junior JV; Delcelo R; Dias-da-Silva MR; Maciel RMB; Galante PAF; Cerutti JM
    BMC Med Genomics; 2019 Jul; 12(1):104. PubMed ID: 31288802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salinomycin and its derivatives as potent RET transcriptional inhibitors for the treatment of medullary thyroid carcinoma.
    Alqahtani T; Kumarasamy VM; Huczyński A; Sun D
    Int J Oncol; 2020 Jan; 56(1):348-358. PubMed ID: 31746350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.